HemCon Medical Technologies Will Appeal Patent Judgment

PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies, Inc., announced today that it will appeal a permanent injunction entered by a US District Court in New Hampshire based on a patent held by Marine Polymer Technologies, Inc. The injunction enjoins further manufacture, use and sale of HemCon’s HEMCON® BANDAGE, CHITOFLEX® DRESSINGS, HEMCON® DENTAL DRESSINGS and any other products which are no more than colorably different from those products. HemCon intends to file a motion for an emergency stay of the injunction during the pendency of the appeal."HemCon will urge on appeal that the Marine Polymer patent is not infringed and/or is invalid, and ask the appellate court to overturn or vacate the judgment. We firmly believe that the lower court made the wrong decision and we are hopeful that the Court of Appeals will correct this and find that HemCon’s products do not infringe the patent or that the patent is invalid,” said John W. Morgan, HemCon's President and Chief Executive Officer.
Marine Polymer sued HemCon in 2006, alleging that HemCon had violated its patent covering a biocompatible chitosan compound. Marine Polymer’s patent describes a chitosan compound that is derived from the sterile culturing of marine micro algae.
HemCon uses a chitosan compound to manufacture highly effective bandages that have been used in battlefield conditions by the U.S. military, among others. HemCon does not use chitosan that is derived from sterile culturing of micro algae, as described in the Marine Polymer patent.
HemCon has separately initiated a proceeding to reexamine the validity of the patent through the US Patent & Trademark Office. In 2009, HemCon filed a request with the Patent Office to reexamine, and possibly invalidate or limit, Marine Polymer’s patent in light of prior publications about chitosan. The Patent Office granted the Request for Reexamination in November 2009. On April 1, 2010, the Patent Office issued a first office action, rejecting all claims of Marine Polymer’s patent. Marine Polymer has filed a response canceling some patent claims and arguing that the remaining claims are valid as originally issued.

New Ultra-Thin Surgical Patch Has Endless Possibilities

Throughout the decades, surgeons have typically used stitches and staples to close up wounds. They may even use sheets several millimeters thick coated with fibrin, a protein that makes blood clot and is glue-like but which can cause unwanted sticking to nearby tissue.

Now, Japanese scientists have revealed a new, cutting edge surgical ‘nano-sheet’ they have developed that is one thousand times thinner than Cellophane that can patch up internal wounds before dissolving inside the body.

This transparent adhesive sheeting is made from a substance derived from crab shells and a viscous gum from algae and is only 75 nanometers thick. A nanometer is one-billionth of one meter.

"This is the world's thinnest adhesive plaster," said Toshinori Fujie, a researcher involved in the joint project by Tokyo's private Waseda University and the National Defense Medical College.


"We know food Cellophane clings on to the surface of various objects. We have made a sheet ultimately thin... so that it is highly flexible and can stick to organs well with no glue," he told AFP.

The experiment, which was repeated several times, consisted of using the new nano-sheet to patch a six-millimeter-wide hole in a dog’s lung.

The sheet proved to have the strength to stand up under the pressure of the dog’s respiration and allow the wounds to heal within a month without a visible trace, according to Fujie.

Researchers hope to launch human clinical trials in three years.

The sheets might also prove to be useful in treating external wounds in the future as well.

"Organs repaired with this sheet do not have scars, unlike after stitches," Fujie said. "We believe this could also be true on the skin."

If the tests show that it is effective externally, it could open up a world of applications such as being applied to wounds from surgery in breast cancer patients, he said.

"Some people also want to use this for treating bed sores. The next application will definitely be on the skin," he said.

Fujie says that the inventors have been exploring all possibilities, even cosmetic uses such as stretching out wrinkles or holding skin conditioners in place.

"As this is transparent on the skin, you could be wearing a face pack while working in the office," he said.

Celox-A delivery system

Just recieved the Video of Celox-A delivery system I would like to share with you all below and the Pdf downloadable from Adrive and verified safe HERE

HemCon Medical Technologies Leverages Sangui Technology to Expand its Wound Care Products Line

PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies Inc. today announced it will use Witten, Germany-based SanguiBioTech GmbH’s ChitoSkin technology platform to help further innovations in hemostatic bandages and wound care dressings for the acute care market.
Under the terms of the agreement, HemCon will leverage Sangui’s technology platform to enhance and expand its product offerings for surgical and wound care. HemCon developed the chitosan-based hemostatic HemCon® Bandages and ChitoFlex® dressings that are used by military and medical first responders as well as health care professionals around the globe.
“We explored a wide variety of technology platforms to add to our new surgical and wound care offerings and feel that the Sangui chitosan platform offers great opportunities to enhance our solutions,” said John W. Morgan, president and CEO of HemCon. “We’re committed to continuing our investment to develop new choices for medical professionals and consumers. This agreement is an important step forward in realizing the full potential of chitosan-based products.”
SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. Sangui BioTech International focuses on vascular and hemostasis products. The firm specializes in developing oxygen-carrying agents to treat blocked arteries, anemia or acute blood loss through SanguiBioTech GmbH.
“We are proud to enter into an agreement with HemCon and offer our chitosan platform to help innovate new surgical and wound care products,” said Sangui Managing Director Hubertus Schmelz. “There is definitely a demand for products that can adapt to specific medical needs, especially as it relates to wound care.”
HemCon retains exclusive worldwide market and distributing rights for products developed under this structured financial agreement. HemCon will submit developed products for U.S. approvals to the FDA, while Sangui will prepare documentation for registration in the European Union.

Celox

CELOX is an innovative new hemostat designed to bond with specific sites which are present on the surface of red blood cells and platelets to make a gel like clot /plug. This process is totally different from the body’s normal clotting mechanisms. CELOX is a proprietary blend of materials covered by 3 international patent applications.
CELOX contains a natural marine polymer, Chitosan.
Chitosan is a highly purified polysaccharide derivative of shrimp shells.
Chitosan is used widely and is in such products as bandages, medical devices diet aids and some cosmetics. It is an approved food ingredient.

Chitosan and Emergency Hemostats

Chitosan is a derivative of solid waste from shell fish processing and can be extracted from fungus culture. Chitosan is a water insoluble cationic polymeric material.
Chitosan is converted to glucosamine by the enzyme lysosyme and is therefore excreted from the body naturally. It is not necessary to remove chitosan from the body. The chemical properties of chitosan related to hemostatis possibly include: molecular weight, extent of ionization, counter ion, degree of deacetylation, and degree of crystallinity. Also, its ability to bind with tissues are a function of these parameters. Chitosan can be used in medical and surgical procedures by its direct application to a bleeding surface using the various physical forms such as powder, solution, coating, film, hydrogel, and filament composite.
A recent review detailing the role of new hemostatic agents for battlefield hemorrhage control describes the interest in and necessary specifications for such materials. As a consequence, the Defense Department authorized the development and use of three deployable and FDA approved hemostatic agents: Zeolite "Quikclot" and chitosanic "Hemcon" and the American Red Cross Fibrin Dressing.
Celox
CELOX is a proprietary blend of materials that contains Chitosan. It is both safe for the caregiver and the victim. It can control the most severe arterial bleeding, even when applied within moments of the onset of high pressure, high volume bleeds.

Quikclot
QuikClot® hemostatic agent is a molecular sieve, sifting molecules by size. When QuikClot® comes into contact with blood in and around a wound, it rapidly takes in the smaller water molecules from the blood. The larger platelet and clotting factor molecules remain in the wound in a highly concentrated form. This promotes extremely rapid natural clotting and prevents severe blood loss.

Hemcon
HemCon Bandages work by becoming extremely sticky when in contact with blood. This adhesive-like action seals the wound and controls bleeding. HemCon products are fabricated from chitosan, a naturally occurring, bio-compatible polysaccharide. Because chitosan has a positive charge, it attracts red blood cells, which have a negative charge. The red blood cells create a seal over the wound as they are drawn into the bandage, forming a very tight, coherent seal.

Abbott
A potent hemostatic agent intended for use in the management of bleeding wounds, including vascular access sites to peripheral puncture sites